SpyGlass Pharma reported net income of -$19.86M for the quarter ended Jun 2026. This income statement covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.79M | 2.12M | 2.20M | 33.45M |
| Operating items | ||||
| Research & DevelopmentR&D | 7.33M | 10.94M | ||
| Selling, General & AdministrativeSG&A | 1.96M | 11.03M | ||
| Operating ExpensesOpex | 9.30M | 21.97M | ||
| Operating IncomeOp. Inc | -9.30M | -21.97M | ||
| EBIT | -9.30M | -21.97M | ||
| Non-operating items | ||||
| Interest & Investment IncomeInt & Inv Inc | 0.62M | 2.10M | ||
| Non Operating IncomeNon Op. Inc. | 0.62M | 2.10M | ||
| Net income details | ||||
| EBT | -8.68M | -19.86M | ||
| Profit After TaxPAT | -8.68M | -19.86M | ||
| Income from Continuing OperationsIncome (Continuing) | -8.68M | -19.86M | ||
| Consolidated Net IncomeConsol Net Inc. | -8.68M | -19.86M | ||
| Income towards Parent CompanyParent Net Inc | -8.68M | -19.86M | ||
| Net Income towards Common StockholdersNet Income | -8.68M | -19.86M | ||
| Additional items | ||||
| EPS (Basic) | -3.81 | -0.59 | ||
| EPS (Diluted) | -3.81 | -0.59 | ||
| Shares Outstanding | 1.79M | 2.28M | 2.22M | 33.44M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.79M | 2.28M | 2.22M | 33.44M |
| EBITDA | -9.30M | -21.97M |